Stem cell therapy, an evolving, progressive field of therapeutics has shown several successes in areas where classic treatments failed to prevent or stop disability. Starting in 2009, twenty two sequential patients with progressive Multiple Sclerosis (MS) courses were treated with Autologous Bone Marrow Mononuclear stem cells (BM-MNSCs). The cells were given both intravenously and intrathecally. Using the Expanded Disability Status Scale (EDSS) score for evaluation, our data indicates that the majority of the patients benefited on the average one point on the scale. This paper adds to the body of evidence suggesting the safety and efficacy of autologous BM-MNSCs in the treatment of MS and awaits validation through larger, randomized studies.

中文翻译：

---

自体骨髓干细胞用于治疗多发性硬化症。

干细胞疗法是一个不断发展、进步的治疗领域，在传统疗法无法预防或阻止残疾的领域取得了一些成功。从 2009 年开始，22 名患有进行性多发性硬化症 (MS) 的连续患者接受了自体骨髓单核干细胞 (BM-MNSC) 治疗。细胞通过静脉内和鞘内给予。使用扩展残疾状态量表（EDSS）评分进行评估，我们的数据表明，大多数患者在量表上平均受益一分。本文补充了大量证据，表明自体 BM-MNSC 治疗 MS 的安全性和有效性，并等待通过更大规模的随机研究进行验证。